Bank of America
KTTAW icon

Bank of America’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Bank of America’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$2 – 7863
2023
Q2 		$2 Buy
+100
New +$3 ﹤0.01% 7640

Other funds holding KTTAW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America's KTTAW Position: Q3 2023 in Review

Bank of America sold out of Pasithea Therapeutics Warrants (KTTAW) in Q3 2023, closing a stake of 100 shares — an estimated $2 sold.

Bank of America first reported a position in KTTAW in Q2 2023 and held it in 1 quarter. The position peaked at $2 in Q2 2023. 7 funds tracked by Wall St. Rank hold KTTAW as of Q3 2023.

  • Bank of America reported no remaining Pasithea Therapeutics Warrants position as of Q3 2023 after selling out during the quarter.
  • Bank of America sold 100 Pasithea Therapeutics Warrants shares in Q3 2023, an estimated $2.
  • Bank of America first reported a position in Pasithea Therapeutics Warrants in Q2 2023 and held it in 1 quarter.
  • Bank of America's Pasithea Therapeutics Warrants position peaked at $2 in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q3 2023.

Based on Bank of America's 13F filing for Q3 2023, filed 14 Nov 2023.